Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines

被引:74
作者
Brandon, EFA
Bosch, TM
Deenen, MJ
Levink, R
van der Wal, E
van Meerveld, JBM
Bijl, M
Beijnen, JH
Schellens, JHM
Meijerman, I
机构
[1] Univ Utrecht, Fac Pharmaceut Sci, Sect Drug Toxicol, Dept Biomed Anal, NL-3584 CA Utrecht, Netherlands
[2] Slotervaart Hosp, Netherlands Canc Inst, Dept Pharm & Pharmacol, Amsterdam, Netherlands
[3] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Med Oncol & Expt Therapy, Amsterdam, Netherlands
关键词
genetic polymorphisms; IGROV-1; HepG2; CaCo-2; LS180 cytochrome P450; phase II enzymes; drug transporters;
D O I
10.1016/j.taap.2005.05.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Human cell lines are often used for in vitro biotransformation and transport studies of drugs. In vivo.. genetic polymorphisms have been identified in drug-metabolizing enzymes and ABC-drug transporters leading to altered enzyme activity, or a chance in the inducibility of these enzymes. These genetic polymorphisms could also influence the outcome Of Studies using human cell lines. Therefore, the aim of our study was to pharmacogenotype four cell lines frequently used in drug metabolism and transport studies, HepG2, IGROV-1, CaCo-2 and LS180, for genetic polymorphisms in biotransformation enzymes and drug transporters. The results indicate that, despite the presence of some genetic polymorphisms, no real effects influencing the activity of metabolizing enzymes or drug transporters in the investigated cell lines are expected. However, this characterization will be an aid in the interpretation of the results of biotransformation and transport studies using these in vitro cell models. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 79 条
[31]   Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene:: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients [J].
Holthe, M ;
Rakvåg, TN ;
Klepstad, P ;
Idle, JR ;
Kaasa, S ;
Krokan, HE ;
Skorpen, F .
PHARMACOGENOMICS JOURNAL, 2003, 3 (01) :17-26
[32]   Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy [J].
Holthe, M ;
Klepstad, P ;
Zahlsen, K ;
Borchgrevink, PC ;
Hagen, L ;
Dale, O ;
Kaasa, S ;
Krokan, HE ;
Skorpen, F .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 58 (05) :353-356
[33]   Variations of the bilirubin uridine-diphosyphoglucuronosyl transferase 1A1 gene in healthy Taiwanese [J].
Huang, CS ;
Luo, GA ;
Huang, MJ ;
Yu, SC ;
Yang, SS .
PHARMACOGENETICS, 2000, 10 (06) :539-544
[34]  
Innocenti F, 2001, DRUG METAB DISPOS, V29, P686
[35]   Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects [J].
Ito, S ;
Ieiri, I ;
Tanabe, M ;
Suzuki, A ;
Higuchi, S ;
Otsubo, K .
PHARMACOGENETICS, 2001, 11 (02) :175-184
[36]  
Jerónimo C, 2002, CANCER EPIDEM BIOMAR, V11, P445
[37]  
KATO SJ, 1994, CANCER EPIDEM BIOMAR, V3, P515
[38]   Identification of functionally variant MDR1 alleles among European Americans and African Americans [J].
Kim, RB ;
Leake, BF ;
Choo, EF ;
Dresser, GK ;
Kubba, SV ;
Schwarz, UI ;
Taylor, A ;
Xie, HG ;
McKinsey, J ;
Zhou, S ;
Lan, LB ;
Schuetz, JD ;
Schuetz, EG ;
Wilkinson, GR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (02) :189-199
[39]   CYP2A6*6, a novel polymorphism in cytochrome P450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity [J].
Kitagawa, K ;
Kunugita, N ;
Kitagawa, M ;
Kawamoto, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (21) :17830-17835
[40]   The significance of the homozygous CYP2A6 deletion on nicotine metabolism:: A new genotyping method of CYP2A6 using a single PCR-RFLP [J].
Kitagawa, K ;
Kunugita, N ;
Katoh, T ;
Yang, MH ;
Kawamoto, T .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 262 (01) :146-151